Drug · DIN 02475928
STEGLUJAN
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since February 3, 2021; first marketed June 13, 2018.
- Drug Identification Number (DIN)
- 02475928
- Company (DIN owner)
- Merck Canada IncKirkland, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Combinations of oral blood glucose lowering drugs A10BD
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ERTUGLIFLOZIN | 15 MG | |
| SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) | 100 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 22, 2018: NOC 20884New Drug Submission (NDS)
Other DINs named STEGLUJAN
- DIN 02475901 · Cancelled Post Market